Haemonetics Corporation
HealthcareNYSE:HAE · New York Stock Exchange
-$1.64 today
Vol 1.05M · Avg 0.84M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$1.3B of revenue converted into $97.3M of net income for the selected period. Gross margin is 57.4% and net margin is 7.4%, showing how much revenue survives after costs and taxes. EPS is $2.02, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3B -2.0% | $1.4B +4.0% | $1.3B +12.0% | $1.2B +17.7% | $993.2M | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $590.4M +1.4% | $582.3M -2.5% | $597.1M +9.4% | $545.8M +18.0% | $462.4M | $344.8M | $725.6M | $804.0M |
| Gross Profit | $743.6M -4.5% | $778.5M +9.4% | $711.9M +14.3% | $622.9M +17.4% | $530.8M | $10.3B | $8.9B | $7.6B |
| Gross Margin | 55.7% -1.5pp | 57.2% +2.8pp | 54.4% +1.1pp | 53.3% -0.1pp | 53.4% | 45.5% | 9.8% | 28.9% |
| Research & Development | $59.8M -13.9% | $69.4M +10.1% | $63.0M +7.5% | $58.6M +6.2% | $55.2M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $442.4M +4.8% | $422.1M +0.3% | $420.8M +12.5% | $374.0M +12.6% | $332.2M | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $502.2M -9.8% | $556.7M +1.8% | $547.0M +17.2% | $466.8M +3.7% | $450.0M | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $155.7M +43.0% | $108.9M +22.9% | $88.6M +4.5% | $84.8M -2.0% | $86.5M | $1.2B | $374.2M | $1.2B |
| EBITDA | $312.4M -12.2% | $356.0M +20.5% | $295.5M +17.2% | $252.0M +31.4% | $191.7M | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | 23.4% -2.7pp | 26.2% +3.6pp | 22.6% +1.0pp | 21.6% +2.3pp | 19.3% | 10.0% | 5.6% | 46.3% |
| Operating Income | $241.4M +8.8% | $221.8M +34.5% | $164.9M +5.7% | $156.0M +93.2% | $80.8M | $10.6B | $12.3B | $14.0B |
| Operating Margin | 18.1% +1.8pp | 16.3% +3.7pp | 12.6% -0.8pp | 13.4% +5.2pp | 8.1% | 18.7% | 16.6% | 24.1% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $28.7M +194.5% | $9.7M -25.1% | $13.0M -11.0% | $14.6M -14.5% | $17.1M | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | -$113.4M -1063.3% | -$9.7M +25.1% | -$13.0M +11.0% | -$14.6M +14.5% | -$17.1M | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | $128.0M -39.6% | $212.1M +39.6% | $151.9M +7.4% | $141.4M +122.2% | $63.6M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | 9.6% -6.0pp | 15.6% +4.0pp | 11.6% -0.5pp | 12.1% +5.7pp | 6.4% | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | $30.7M -30.8% | $44.4M +29.4% | $34.3M +31.9% | $26.0M +28.4% | $20.3M | $666.8M | $1.3B | -$1.6B |
| Net Income | $97.3M -42.0% | $167.7M +42.6% | $117.6M +1.9% | $115.4M +166.1% | $43.4M | $5.0B | $4.9B | $4.8B |
| Net Margin | 7.3% -5.0pp | 12.3% +3.3pp | 9.0% -0.9pp | 9.9% +5.5pp | 4.4% | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | $2 -38.1% | $3 +42.7% | $2 +2.2% | $2 +167.1% | $1 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | $2 -38.1% | $3 +44.5% | $2 +2.2% | $2 +166.7% | $1 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $47.2M -6.3% | $50.3M -0.7% | $50.7M -0.2% | $50.8M -0.5% | $51.0M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $47.4M -6.7% | $50.7M -1.3% | $51.4M -0.0% | $51.4M +0.1% | $51.4M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
$3.84B
Concentra Group Holdings Parent, Inc.
NYSE:CON
$3.60B
Warby Parker Inc.
NYSE:WRBY
$3.25B
Integer Holdings Corporation
NYSE:ITGR
$3.09B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
Premier, Inc.
PINC
$2.34B
LeMaitre Vascular, Inc.
NASDAQ:LMAT
$2.10B
DENTSPLY SIRONA Inc.
NASDAQ:XRAY
$2.02B
Bausch Health Companies Inc.
NYSE:BHC
$1.89B
QuidelOrtho Corporation
NASDAQ:QDEL
$963.54M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does HAE generate?
Haemonetics Corporation (HAE) reported $1.33B of revenue in fiscal 2026.
Is HAE profitable?
Haemonetics Corporation (HAE) reported $97.31M of net income, with a net margin of 7.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.